Posted by Michael Wonder on 19 Aug 2016
NICE issues draft guidance on the first-line use of sorafenib tosylate (Nexavar) in advanced/metastatic hepatocellular carcinoma
19 August 2016 - The merits of Nexavar in liver cancer have been reviewed by NICE under the CDF rapid reconsideration process.
Sorafenib tosylate is not recommended for treating advanced hepatocellular carcinoma in adults when surgical or locoregional therapies have failed or are not suitable.
Nexavar will be considered at a second appraisal committee meeting (date is yet to be determined).
